+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
O

Actively Recruiting

Researchers are conducting an observational study to collect baseline growth data in children diagnosed with Idiopathic Short Stature ISS. The study aims to better understand growth patterns by measuring various growth-related factors over time in this pediatric population aged between 2 and 16 years, with a focus on children experiencing significant short stature. This long-term study is sponsored by BioMarin Pharmaceutical to help characterize how children with ISS grow compared to typical growth standards. Participants will be observed without receiving any study treatments. Growth measurements such as annualized growth velocity, height Z-score, standing height, body mass index BMI, and BMI Z-score will be collected every six months. The study will also record medical events and explore relationships between genetic variants and growth velocity. This observational approach allows tracking changes over time without intervention. Families will be involved in regular assessments every six months for up to 15 years. These evaluations include physical growth measurements and monitoring of medical events related to short stature. Data from historic growth hormone hGH stimulation tests and treatment status will also be considered. The studys primary outcomes focus on changes in growth metrics, while secondary outcomes assess medical event rates and genetic associations. Participation requires ongoing cooperation for scheduled measurements and consent from parents or guardians.

Age: 2Years - 16YearsAll Genders
38 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
37 locations
E

Actively Recruiting

Researchers are evaluating LPCN 1154A as a possible treatment for postpartum depression PPD in women with severe symptoms. This phase 3 trial aims to find out if LPCN 1154A can reduce depressive symptoms and how well it is tolerated, including potential side effects. Participants receive either oral LPCN 1154A tablets or placebo tablets for 48 hours. The study is randomized and blinded to compare these two groups in parallel. The treatment phase lasts for 48 hours. During the study, participants will be assessed for changes in depression severity using the Hamilton Depression Rating Scale HAM-D from baseline to hour 60, along with other measures at hour 12 and day 30. Safety and side effects are monitored throughout. The participation spans from screening through treatment and follow-up assessments.

Age: 15Years - 45YearsFEMALEPhase 3
16 locations
P

Actively Recruiting

Researchers are evaluating the effects and safety of solriamfetol in adults with binge eating disorder BED. This Phase 3 trial compares two doses of solriamfetol 150 mg and 300 mg with a placebo to better understand their impact on BED symptoms. Participants must be aged 18 to 55 with a diagnosis of BED based on DSM-5 criteria. Participants will be randomly assigned to one of three groups receiving either solriamfetol 150 mg, solriamfetol 300 mg, or placebo tablets, all taken once daily for 12 weeks. This randomized, double-blind study will assess how these treatments affect binge eating episodes over the course of the trial. During the 12 weeks, participants will be monitored for changes in the number of binge eating episodes. Safety and efficacy will be evaluated through regular assessments. All study-related care, including medication and visits, will be provided at no cost, and the total participation duration is approximately 12 weeks.

Age: 18Years - 55YearsAll GendersPhase 3
45 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
U

Actively Recruiting

Healthy Volunteer

This research aims to evaluate a new behavioral intervention using real-time functional magnetic resonance imaging fMRI neurofeedback to reduce the return of threat expectancy in healthy adults. The study focuses on understanding why fear returns after exposure therapy by studying spontaneous recovery in threat learning through Pavlovian conditioning and extinction. It also explores the relationship between memory control ability and this recovery process, using brain activity between the prefrontal cortex and hippocampus as key targets. Participants will be randomly assigned to one of two groups an active neurofeedback group receiving real-time feedback designed to enhance memory control by reinforcing negative connectivity between the right dorsal-lateral prefrontal cortex and hippocampus, or a control group receiving sham neurofeedback with similar instructions but no actual feedback. The intervention involves four fMRI sessions conducted within 60 days, aiming to strengthen participants ability to inhibit memories linked to threat. Throughout the study, participants will undergo multiple fMRI sessions to measure spontaneous recovery behavior and neurofeedback learning. Researchers will assess how well participants control memory and how this influences threat expectancy. Monitoring includes behavioral tests and brain imaging to evaluate the impact of the neurofeedback intervention. The total study period for each participant will be up to 60 days from the first to the fourth fMRI session.

Age: 18Years - 50YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how behavioral and sensorimotor responses measured by the BlinkLab Dx1 smartphone app relate to autism diagnoses in children aged 2 to 11. This observational study focuses on children who have undergone neurodevelopmental assessments within the past 12 months, using data to develop and assess a machine learning algorithm for autism diagnosis. The goal is to understand if patterns recorded by the app can help distinguish children with autism from those without, based on prior clinical diagnoses. Participants will complete two brief video-based sessions at home using the BlinkLab Dx1 app, which presents visual and auditory stimuli and records reflexive responses and repetitive behaviors. Caregivers will also complete a questionnaire about symptoms and development. The study involves no treatment or medical intervention and uses previously collected clinical data as a reference standard. The dataset is split into training and testing groups to develop and evaluate the algorithms accuracy in classifying autism status. During the study, researchers will collect app data and paired clinical diagnoses to assess diagnostic performance, including sensitivity and specificity. Additional measures include adverse events, usability, and autism symptom severity using the SRS-2 assessment. Participation involves remote sessions and questionnaires, with data collected prospectively and retrospectively. The study lasts for up to 30 days per participant and monitors for safety and usability during this period.

Age: 2Years - 11YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the safety and proper dosing of the drug CLR 125 in patients with advanced triple negative breast cancer, a type of breast cancer that lacks certain hormone receptors. This Phase 1 trial aims to find the best dose and treatment schedule for future studies while monitoring side effects and antitumor activity, including treatment response and survival outcomes. The study is sponsored by Cellectar Biosciences, Inc. and plans to enroll up to 60 patients. Participants receive CLR 125 through an intravenous infusion given four times per cycle, with each cycle lasting eight weeks. There are several dosing groups with different dose levels and schedules, and participants may receive up to four cycles depending on the group. Some patients will also receive a single dose of CLR 131 to measure radiation delivery, undergoing scans and blood draws during this dosimetry phase. During the trial, participants visit the clinic every three weeks for checkups and tests. They will report any side effects or new medications throughout the study, which includes follow-up for up to one year after treatment ends. Researchers assess safety by tracking side effects and measure efficacy through tumor response rates, progression-free survival, overall survival, and duration of clinical benefit.

Age: 18Years +All GendersPhase 1
4 locations

1-10 of 13

1